Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.
Feature|Articles|September 11, 2023
- Pharmaceutical Executive: September 2023
- Volume 43
- Issue 9
Ahead of the Curve: Pharm Exec Profiles Five Recent Drug Launches
Pharm Exec’s latest selections of notable biopharma brand launches—some with novel preemptive approaches—highlight products that are paving uncharted paths across a diverse disease landscape.
Advertisement
Selections were made by Pharmaceutical Executive's editorial staff, with close input from Editorial Advisory Board members.
Articles in this issue
about 3 years ago
Pharmaceutical Executive, September 2023 Issue (PDF)about 3 years ago
A New Era of Ethical Leadershipabout 3 years ago
Survival Story: Enhertuabout 3 years ago
Gut Instinct: Rebyotaabout 3 years ago
Delaying Disease Onset: Tzieldabout 3 years ago
New Beginnings: Sunlencaabout 3 years ago
A Heartfelt Solution: Camzyosabout 3 years ago
Fortifying Defenses Pre-Patent Cliffabout 3 years ago
New Product Planning: The Function's Evolution in Pharmaabout 3 years ago
No Rate Relief in Sight for BiotechAdvertisement
Related to this article
How earlier signals of misconnection may help pharma identify trust breakdowns before they show up as lagging measures in adherence, initiation, engagement, and outcomes.
Advertisement
Advertisement
Trending on PharmExec
1
Viatris Acquires Pacira BioSciences for $1.65 Billion
2
FDA Approves Tecentriq for Stage III dMMR Colon Cancer
3
Roundup: TRexBio & Retension Pharmaceuticals Announce IPO Pricing
4
The Most Important Lessons Learned from Building CGT Supply Chains: LogiPharma 2026
5